Intravenous Light Therapy Demonstrates Huge Potential for Aesthetic Medicine
In anticipation of its official European launch at the 14th Aesthetic & Anti-Aging Medicine World Congress (AMWC) this month, UVLrx Therapeutics™ is pleased to share its intravenous light therapy treatment system, the model UVL1500, to assist in aesthetic post-surgical and non-surgical patient recovery by reducing inflammation, pain, and accelerating wound repair. The company has started to collect patient data that showcases the benefits of light wavelengths utilized by its UVLrx™ Treatment System* for reducing inflammation, a key issue following invasive and non-invasive aesthetic procedures today.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160330006331/en/
“According to the International Society of Aesthetic Plastic Surgery , more than 20 million cosmetic surgical and non-surgical procedures were performed in 2014,” said Michael Harter, CEO and president of UVLrx. “The success of those procedures depends heavily on quality of recovery and patient response, which is why inflammation abatement is so important for the industry. By immediately reducing inflammation caused by an aesthetic procedure, our technology may minimize pain and accelerate healing, which in turn may lead to better results and a more satisfied post-op patient.”
Dr. Daniel Knight, MD, and Denise Moss, RN, in conjunction with White Clover Wellness & Research Center in Shreveport, Louisiana, have clinical trial results that demonstrate recovery improvement using an investigational device version of the UVLrx technology (Model UVL1000) by reducing pain, edema and erythema in several of their post-surgical/non-surgical aesthetics patients. In fact, all fifteen patients they treated recently in the clinical trial reported improvement in overall quality of life and confidence in their recovery progression. The patients’ positive perception of their improved recovery even appeared to translate into the patients’ perception of how successful the results of their aesthetic procedures were overall, in some cases even accelerating results.
In this clinical trial, patients were treated and subsequently monitored across four evaluation points: baseline and days 3, 7 and 14 post-procedure. Subjects reported improvement by day 3 evaluation, and no adverse effects have been observed. UVLrx patients reported a significant reduction in pain and presented with impressive clinical results days after undergoing non-surgical procedures such as transdermal ultrasound skin tightening, which has often been described as painful and requiring several months to observe clinical results. The level of post-procedural progress observed in this study by day 7 resembled results typically observed in months 2 and 3 post procedure.
“Aesthetic physicians’ work is judged not only by procedural results but also by their patients’ recovery experiences,” commented Rowland Hanson, chairman of UVLrx. “Given the recent Centers for Disease Control and Prevention (CDC) guidelines regarding opiates in the U.S., we expect physicians to seek alternative pain management therapies such as the UVLrx™ Treatment System in order to avoid prescribing addictive and potentially fatal painkillers. Because many aggressive aesthetic procedures have required powerful opiates in the past, intravenous light therapy has the potential to mitigate this crisis and help aesthetics patients who suffer from post-procedural pain.”
Ultraviolet Blood Irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion of drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.
To learn more, visit UVLrx.com and stop by the UVLrx Therapeutics booth (F18) at the 14th Aesthetic & Anti-Aging Medicine World Congress from March 31st to April 2nd . To watch a webinar about UVLrx’s technology, please visit https://youtu.be/_WxFjQIekzM .
The UVLrx Station™ Model UVL1500 is not available for sale in the U.S.
* References to published specific wavelength studies available upon request.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to evidence-based medicine in the field of light therapy and offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. In addition to two Nobel Prizes and NASA-backed research, hundreds of international clinical trials have verified the health benefits of UV and other wavelengths of light utilized in the UVLrx™ Treatment System. For more information, please visit http://uvlrx.com .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-GILEAD-SCIENCES,-INC.14.12.2017 22:32 | pressemeddelelse
Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors
UNIPRINT.NET14.12.2017 20:09 | pressemeddelelse
UniPrint Infinity Now Available in Epic App Orchard
FINEOS14.12.2017 16:59 | pressemeddelelse
FINEOS Announces Three New Customers in the Cloud
UNIPRINT.NET14.12.2017 16:54 | pressemeddelelse
UniPrint Infinity Now Available in Epic App Orchard
PEACE-FORUM14.12.2017 16:21 | pressemeddelelse
Abdullah bin Zayed Honors Winners of the Al Hassan Bin Ali Award 2017 as Part of the Fourth Annual Forum for Promoting Peace in Muslim Societies
WA-KYMETA/INTELSAT14.12.2017 16:02 | pressemeddelelse
Kymeta Announces Commercial Availability of KĀLO™ Mobile Internet Access Services
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum